tbuckley/cabot-search huggingface dataset:
PTH-122 Assessing The Impact of A Nutritional Course to A Third World Country - Lessons from A BSG-Funded Delegation to Iraq
Authors: HN Haboubi, N Al-Mossawi, M Boyle, A Evans, A Alhamdani, M Jawad, M Esmail, A Hassan, NA Haboubi, W Haboubi, H Twaij, NY Haboubi
Journal: Gut (2016)

<h3>Introduction</h3> Good nutrition is pivotal for ensuring an individuals health and wellbeing. The Iraqi Healthcare system has suffered years of underinvestment, war and turmoil. In particular, services dealing with nutrition and dietetics are often overlooked or entirely non-existent in Iraqi hospitals leading to a significant adverse effect on overall health outcomes. We investigate the usefulness of an intensive nutritional course in improving knowledge and confidence amongst healthcare professionals in Iraq. <h3>Methods</h3> A BSG-funded delegation visited the University of Kufa, Iraq in January 2016 to deliver an intensive four-day course on clinical nutrition based on the BSG, BDS, and BAPEN guidelines. Each day was dedicated to specific learning outcomes in general dietetic assessment, special situations (including GI nutrition &amp; trauma), paediatric nutrition and obesity nutrition. This free for all course received 20 external CPD credits from the Royal College of Physicians. A detailed pre-course questionnaire was distributed to evaluate understanding of common nutritional problems and confidence in managing these. A subsequent questionnaire one-month following the course evaluated changes to confidence (using a standardised 5 point confidence Likert scale). <h3>Results</h3> 147 delegates attended the course from 8 of the 19 Iraqi governates. Completed post-course questionnaires were available for 69 individuals (47% response rate). Whilst 88% of attendees did not feel confident diagnosing malnutrition before the course, this improved to 97% of respondents with &gt;3/5 confidence in the post-course questionnaire (67% scoring &gt;4/5). Other observed improvements included mean confidence scores for biochemical workup of patients with suspected malnutrition (2.9 pre-course compared to 4.3 post-course, p &lt; 0.01). In fact, for the 40 sessions organised during the 4 day course, all showed a significant improvement in post-course confidence. <h3>Conclusion</h3> Clinical nutrition is an often under taught component of medical education. It’s importance; particularly to war-torn developing countries that have no dietetic infrastructure should not be understated. A BSG-funded delegation was able to deliver an intensive 4 day conference to health leaders in Iraq and demonstrated improved knowledge and confidence at dealing with nutritional dilemmas. We welcome BSG-funding for such endeavours and thank them for their support. <h3>Disclosure of Interest</h3> None Declared
HDAC Profiling In Mantle Cell Lymphoma Unveils HDAC11 and HDAC10 as Potential Molecular Targets
Authors: Bijal D. Shah, Alejandro Villagra, Oscar Merino, Jennifer Rock-Klotz, Karrune Woan, Edward Seto, Peter Martin, John P. Leonard, Selina Chen-Kiang, Jianguo Tao, Eduardo M. Sotomayor
Journal: Blood (2010)
Validation of biomarkers to predict response to immunotherapy in cancer: Volume II — clinical validation and regulatory considerations
Authors: Kevin K. Dobbin, Alessandra Cesano, John Alvarez, Rachael Hawtin, Sylvia Janetzki, Ilan Kirsch, Giuseppe V. Masucci, Paul B. Robbins, Senthamil R. Selvan, Howard Z. Streicher, Jenny Zhang, Lisa H. Butterfield, Magdalena Thurin
Journal: Journal for ImmunoTherapy of Cancer (2016)

There is growing recognition that immunotherapy is likely to significantly improve health outcomes for cancer patients in the coming years. Currently, while a subset of patients experience substantial clinical benefit in response to different immunotherapeutic approaches, the majority of patients do not but are still exposed to the significant drug toxicities. Therefore, a growing need for the development and clinical use of predictive biomarkers exists in the field of cancer immunotherapy. Predictive cancer biomarkers can be used to identify the patients who are or who are not likely to derive benefit from specific therapeutic approaches. In order to be applicable in a clinical setting, predictive biomarkers must be carefully shepherded through a step-wise, highly regulated developmental process. Volume I of this two-volume document focused on the pre-analytical and analytical phases of the biomarker development process, by providing background, examples and "good practice" recommendations. In the current Volume II, the focus is on the clinical validation, validation of clinical utility and regulatory considerations for biomarker development. Together, this two volume series is meant to provide guidance on the entire biomarker development process, with a particular focus on the unique aspects of developing immune-based biomarkers. Specifically, knowledge about the challenges to clinical validation of predictive biomarkers, which has been gained from numerous successes and failures in other contexts, will be reviewed together with statistical methodological issues related to bias and overfitting. The different trial designs used for the clinical validation of biomarkers will also be discussed, as the selection of clinical metrics and endpoints becomes critical to establish the clinical utility of the biomarker during the clinical validation phase of the biomarker development. Finally, the regulatory aspects of submission of biomarker assays to the U.S. Food and Drug Administration as well as regulatory considerations in the European Union will be covered.
Efficient Differentiation of Common Marmoset Embryonic Stem Cells Into Hemangioblast-Like Cells by the Inhibition of PI3K-AKT Pathway
Authors: Takenobu Nii, Tomotoshi Marumoto, Hirotaka Kawano, Saori Yamaguchi, Yoko Nagai, Yoshie Miura, Jiyuan Liao, Michiyo Okada, Kenzaburo Tani
Journal: Blood (2011)
OP0062-HPR Efficacy of Tailored Exercise Therapy in Patients with Knee Osteoarthritis and Comorbidity: A Randomized Controlled Trial
Authors: M. De Rooij, M. van der Leeden, J. Cheung, M. van der Esch, A. Arja Häkkinen, D. Haverkamp, L.D. Roorda, J. Twisk, J. Vollebregt, W.F. Lems, J. Dekker
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Exercise therapy is a key intervention in the management of knee osteoarthritis (OA). It is an effective intervention to improve physical functioning and reduce joint pain in patients with knee OA. Comorbidity, which is highly prevalent in OA, interferes with the application of exercise therapy and contributes to non-adherence to exercise therapy. <h3>Objectives</h3> To evaluate the efficacy and safety of tailored exercise therapy on physical functioning in patients with knee osteoarthritis (OA) and comorbidity <h3>Methods</h3> A randomized clinical controlled trial was performed, comparing comorbidity-adapted exercise therapy with a control intervention. The study was conducted in an outpatient rehabilitation center. Patients with a clinical diagnosis of knee OA and at least one of the target comorbidities, i.e., coronary disease, heart failure, type 2 diabetes, COPD or obesity (body mass index≥30kg/m) with severity scores ≥2 on the Cumulative Illness Rating Scale were included. The intervention group received a 20 weeks individualized, comorbidity-adapted exercise program, with 2 sessions of 30 -60 minutes a week. Participants in the control group received their current medical care for knee OA and were placed on a waiting-list for exercise therapy. Measurements were performed at baseline, at 10-weeks, 20-weeks (post-treatment) and 32 weeks (3-months post-treatment). Primary outcome measures: physical functioning (WOMAC subscale physical functioning and six minute walking test). Generalized Estimating Equation analysis was used to estimate group differences over time, adjusting for baseline value of outcome measure. <h3>Results</h3> In total, 126 participants were randomised, of which 63 participants in the experimental group and 63 in the control group. Statistically significant differences were found over time between the intervention and control group with respect to physical functioning WOMAC-pf and the six minute walk test in favour of the intervention group. The improvements in the experimental group were clinically relevant. The mean improvements in the intervention group on physical functioning were 33% on the WOMAC-pf scale and 15% on the six-MWT at 3 months follow up. No serious adverse events occurred during the intervention. <h3>Conclusions</h3> This is the first study showing that tailored exercise therapy is safe and effective in improving physical functioning, in patients with knee OA and comorbidities. These results should encourage clinicians to consider exercise therapy as a treatment option for patients with knee OA, even in the presence of comorbidity. <h3>Disclosure of Interest</h3> None declared
Humans are not the Borg: Personal and social selves function as components in a unified self-system
Authors: Donelson R Forsyth
Journal: Behavioral and Brain Sciences (2016)

Does joining groups trigger a cascade of psychological processes that can result in a loss of individuality and lead to such outcomes as social loafing and poor decision-making? Rather than privileging the self comprising primarily individual qualities as the "true self," a multilevel, multicomponent approach suggests that, in most cases, personal and collective identities are integrated and mutually sustaining.
AB0043 Serum Cytokine Concentrations in Inflammatory Bowel Disease (IBD) and IBD-Related Spondyloarthritis (SPA)
Authors: J. Dmowska-Chalaba, E. Kontny
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Inflammatory bowel disease (IBD) is a group of recurrent gastrointestinal disorders, involving Crohn disease (CD) and ulcerative colitis (UC), that is characterized by chronic mucosal inflammation and extraintestinal symptoms. Rheumatic abnormalities of a broad spectrum of symptoms, from arthralgia to spondyloarthritis (SpA), are the most common extraintestinal manifestations of IBD. The pathogenesis of IBD-related arthritis is unclear. <h3>Objectives</h3> In this study, we analyzed the serum cytokine concentrations (interleukins: IL-10, IL-18, IL-21, IL-23, interferon γ) in patients with IBD-associated spondyloarthritis and patients with IBD not complicated with SpA symptoms. <h3>Methods</h3> The study group consisted of 75 patients (44 female/29 male, age 43,7±12,3 year) suffering from IBD alone (n=35) or with IBD accompanied by arthritis (n=39), i.e. spondyloarthritis (IBD-SpA, n=16) or ankylosing spondylitis (IBD-AS, n=23). The control group included age and sex matched healthy volunteers (n=42). Serum cytokine concentrations were measured using commercially available kits from eBioscience, San Diego, CA, USA (Platinum ELISA for IL-18, ReadySetGo ELISAs for IL-10, IL-21, IL-23, interferon γ). <h3>Results</h3> The concentrations of IL-23 (the mean ± SEM =156 ±14 vs 115±49 pg/ml) and IL-21 (232±79 vs 20.6 ±8 pg/ml) were significantly higher (p&lt;0.0001) in the total group of patients than control sera. Similar significant elevation of IL-21 and IL-23 was found in IBD (146±35 and 133±40 pg/ml, respectively), IBD-SpA (124±48 and 151±37 pg/ml, respectively) and IBD-AS (194±62 and 417±228 pg/ml, respectively) groups comparing with control sera (p≤0.001). There was no significant difference between control and patients groups in the serum concentrations of other tested cytokines, except IL-18. The levels of IL-18 were significantly lower in the sera of IBD-AS group than in healthy volunteers (59±19 vs 180±36 pg/ml, p=0.02). Although we failed to show significant difference in serum cytokine concentrations between IBD and IBD-SpA or IBD-AS patients, in the IBD-AS group there was again tendency to downregulation of serum IL-18 in comparison with patients suffering from IBD alone (59±19 vs 121 ±27 pg/ml, p=0.08). <h3>Conclusions</h3> Significant elevation of serum IL-21 and IL-23 found in IBD patients irrespectively of complication with SpA suggests implication of these cytokines in the underlying disease pathology. On the other hand, diminution of serum IL-18 in IBD-AS may point to protective action of this cytokine in AS development. Supported by grant 2012/05/N/NZ5/02839 from the National Science Centre of Poland. <h3>Disclosure of Interest</h3> None declared
Inducible Expression of Cancer Testis Antigens in Myelodysplastic Syndrome (MDS) Patients Following Treatment with an Oral 5-Azacytidine
Authors: John Powers, Eva Sahakian, Jason A Dubovsky, Tyler Farnum, Emmanuel Berchmans, Douglas G McNeel, Barry S. Skikne, Kyle J MacBeth, Rami S. Komrokji, Javier Pinilla-Ibarz
Journal: Blood (2012)
How changes to drug prohibition could be good for the UK—an essay by Molly Meacher and Nick Clegg
Authors: Molly Meacher, Nick Clegg
Journal: BMJ (2016)

Parliamentarians <b>Molly Meacher</b> and <b>Nick Clegg</b> discuss regulation for cannabis, heroin, and so called legal highs and call for an end to criminal sanctions for the possession and use of all drugs
Effectiveness and Tolerance of Azacitidine for Treating Patients with Chronic Myelomonocytic Leukemia in Community-Based Management.
Authors: Regina Garcia, Maria E Amutio, Manuel Almagro, Alicia Bailen, Jose F Falantes, Marta Garcia, Angela Ibañez, Reyes Sanchotello, Guillermo Sanz
Journal: Blood (2009)
Phase II Study of the Combination of Low-Dose Thalidomide, Prednisone, and Oral Cyclophosphamide (TPC Regimen) in the Treatment of Anemia, Splenomegaly, and Constitutional Symptoms Associated with Myelofibrosis with Myeloid Metaplasia (MMM).
Authors: Ruben A. Mesa, Animesh Pardanani, David P. Steensma, Mark Litzow, William Hogan, Susan Geyer, Wenting Wu, Jerome Zeldis, Ayalew Tefferi
Journal: Blood (2006)
Targeting BCL6 and Germinal Centers (GCs) in Chronic Graft-Versus-Host Disease (cGVHD) Using Direct and Epigenomic Therapies
Authors: Ryan P Flynn, Katelyn Goodman, Jun Qi, Du Jing, Angela Panoskaltsis-Mortari, Zhang Yi, Chen Dong, Xindong Liu, Kelli P A MacDonald, Geoffrey R Hill, Jonathan S Serody, William J Murphy, Leo Luznik, Ivan Maillard, John Koreth, Corey S Cutler, Robert J Soiffer, Joseph H. Antin, Jerome Ritz, Ari M Melnick, James E. Bradner, Bruce R. Blazar
Journal: Blood (2014)
Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Authors: Brad Kahl, John C. Byrd, Ian W. Flinn, Nina Wagner-Johnston, Stephen Spurgeon, Don M Benson, Richard R. Furman, Jennifer R Brown, Steven Coutre, Brian Lannutti, Neil A. Giese, Roger G Ulrich, Heather K Webb, Sissy Peterman, Leanne Holes, Albert S Yu
Journal: Blood (2010)
PWE-017 Prospective Evaluation of The Safety and Efficacy of Switching Stable Patients with Inflammatory Bowel Disease from Remicade™ to Biosimilar Infliximab (IFX)
Authors: KJ Bennett, GA Heap, S Hawkins, T Ahmad
Journal: Gut (2016)

<h3>Introduction</h3> Biosimilar IFX (CT-P13; Remsima<sup>TM</sup>/Inflectra<sup>TM</sup>) became available in the UK in February 2015 offering significant savings to the NHS. Efficacy and safety data in inflammatory bowel disease (IBD) is limited. From May 2015 IBD patients at the Royal Devon and Exeter NHSFT were switched from Remicade<sup>TM </sup>to Biosimilar IFX. We reviewed efficacy and safety data during this switch. <h3>Methods</h3> Treatment was evaluated in IBD patients who met the following criteria: i) Remicade<sup>TM</sup> treatment for greater than 6 months prior to switch ii) minimum follow-up data of 6 months following switch. Disease activity scores (Harvey-Bradshaw Index for Crohn's disease [CD] and Simple Colitis Score for ulcerative colitis [UC]), CRP, drug levels and total anti-drug antibody levels were collected immediately prior to biosimilar switch and then every 16 weeks. All adverse events were recorded. <h3>Results</h3> 104 patients (54 male) met the inclusion criteria with a mean age of 43 years (range 17–71). 73 had CD, 29 had UC and 2 had IBD-unclassified. The median duration of Remicade<sup>TM</sup> therapy prior to switch was 1137 days (95% confidence interval = 933–1290). Missing cases were excluded on a variable by variable basis. There was no significant difference in CRP (median pre-switch = 2, post-switch = 2, <i>P</i> = 0.81) or disease activity score (median pre-switch = 1, post-switch = 1, <i>P</i> = 0.44) after switching from Remicade<sup>TM</sup> to Biosimilar IFX. 85% were in remission before compared with 81% six months following switch (<i>P</i> = 0.51). There was no difference in the number of people with detectable total anti-drug antibody levels (pre-switch = 29, post-switch = 27, <i>P</i> = 0.88) but a fall in drug levels was noted after switching (median pre-switch =5.4, post-switch = 2.8, <i>P</i> = 0.01). 41% had significant anti-drug antibodies pre-switch compared to 36% at 6 months post switch (<i>P</i> = 0.50). 11% of patients had positive anti-drug antibodies with undetectable drug levels pre-switch compared to 7% at 6 months (<i>P</i> = 0.35). 4 patients had adverse events within eight months of switching to biosimilar IFX; 2 minor infusion reactions and 2 anti-TNF induced skin disease. 19 patients stopped within six months of switching; 6 electively, 9 due to loss of response and 4 for other reasons. <h3>Conclusion</h3> This uncontrolled data suggests biosimilar IFX is safe and effective with no significant change observed in CRP, disease severity index and drug antibody levels six months after switch. The fall in IFX drug level after switch warrants further investigation. <h3>Disclosure of Interest</h3> K. Bennett: None Declared, G. Heap Grant/research support from: Hospira, Knapp, Abbvie, MSD, S. Hawkins: None Declared, T. Ahmad Grant/research support from: Hospira, Knapp, Abbvie, MSD
Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis
Authors: Yuli Huang, Xiaoyan Cai, Weiyi Mai, Meijun Li, Yunzhao Hu
Journal: BMJ (2016)

<b>Objectives</b>&nbsp;To evaluate associations between different definitions of prediabetes and the risk of cardiovascular disease and all cause mortality. <b>Design</b>&nbsp;Meta-analysis of prospective cohort studies. <b>Data sources</b>&nbsp;Electronic databases (PubMed, Embase, and Google Scholar). <b>Selection criteria</b>&nbsp;Prospective cohort studies from general populations were included for meta-analysis if they reported adjusted relative risks with 95% confidence intervals for associations between the risk of composite cardiovascular disease, coronary heart disease, stroke, all cause mortality, and prediabetes. <b>Review methods</b>&nbsp;Two authors independently reviewed and selected eligible studies, based on predetermined selection criteria. Prediabetes was defined as impaired fasting glucose according to the criteria of the American Diabetes Association (IFG-ADA; fasting glucose 5.6-6.9 mmol/L), the WHO expert group (IFG-WHO; fasting glucose 6.1-6.9 mmol/L), impaired glucose tolerance (2 hour plasma glucose concentration 7.8-11.0 mmol/L during an oral glucose tolerance test), or raised haemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) of 39-47 mmol/mol<b></b>(5.7-6.4%) according to ADA criteria or 42-47 mmol/mol (6.0-6.4%) according to the National Institute for Health and Care Excellence (NICE) guideline. The relative risks of all cause mortality and cardiovascular events were calculated and reported with 95% confidence intervals. <b>Results</b>&nbsp;53 prospective cohort studies with 1 611 339 individuals were included for analysis. The median follow-up duration was 9.5 years. Compared with normoglycaemia, prediabetes (impaired glucose tolerance or impaired fasting glucose according to IFG-ADA or IFG-WHO criteria) was associated with an increased risk of composite cardiovascular disease (relative risk 1.13, 1.26, and 1.30 for IFG-ADA, IFG-WHO, and impaired glucose tolerance, respectively), coronary heart disease (1.10, 1.18, and 1.20, respectively), stroke (1.06, 1.17, and 1.20, respectively), and all cause mortality (1.13, 1.13 and 1.32, respectively). Increases in HBA<sub>1c</sub> to 39-47 mmol/mol or 42-47 mmol/mol were both associated with an increased risk of composite cardiovascular disease (1.21 and 1.25, respectively) and coronary heart disease (1.15 and 1.28, respectively), but not with an increased risk of stroke and all cause mortality. <b>Conclusions</b>&nbsp;Prediabetes, defined as impaired glucose tolerance, impaired fasting glucose, or raised HbA<sub>1c</sub>, was associated with an increased risk of cardiovascular disease. The health risk might be increased in people with a fasting glucose concentration as low as 5.6 mmol/L or HbA<sub>1c</sub> of 39 mmol/mol.
Clopidogrel, a P2Y12 Receptor Antagonist, Potentiates the Inflammatory Response in a Rat Model of Peptidoglycan Polysaccharide - Induced Arthritis,
Authors: Analia E Garcia, Sripal R Mada, Mario C Rico, Raul A. De La Cadena, Satya P. Kunapuli
Journal: Blood (2011)
Evaluation of Pro-Angiogenic Activity of Factor XIII (FXIII) in Ischemic Tissue, Heart Transplantation and FXIII-Deficient Mice.
Authors: Aida Inbal, Jonathan Leor, Ehud Skutelsky, David Castel, Radka Holbova, Ganet Schibi, Iris Goldberg, Regina Eskaraev, Rima Dardik
Journal: Blood (2004)
OP0123 Mri-Detected Inflammation Is Associated with Functional Disability in Early Arthritis
Authors: L.E. Burgers, W.P. Nieuwenhuis, H.W. van Steenbergen, E.C. Newsum, T.W.J. Huizinga, M. Reijnierse, S. le Cessie, A.H.M. van der Helm-van Mil
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> MRI sensitively detects inflammation, but the clinical relevance of MRI-detected inflammation is undetermined in early arthritis. Therefore, this cross-sectional study investigated the association between MRI-detected inflammation of hands and feet and functional disability in early arthritis. <h3>Methods</h3> 514 early arthritis patients, consecutively included in the Leiden Early Arthritis Clinic, were studied. At baseline, unilateral 1.5T MRI of the wrist, metacarpophalangeal (MCP) and metatarsophalangeal-joints was made and functional disability was measured using the Health Assessment Questionnaire (HAQ). MRIs were scored for bone marrow oedema (BME), tenosynovitis and synovitis by two readers. The sum of these three features yielded the total MRI-inflammation score. Linear and non-linear regression analyses were performed with HAQ as dependent variable. <h3>Results</h3> The total MRI-inflammation score was associated with the HAQ-score (β=0.014, p&lt;0.001), as were BME (β=0.015, p&lt;0.001), tenosynovitis (β=0.046, p&lt;0.001) and synovitis (β=0.039, p&lt;0.001) separately. Analysing these three MRI-features in one multivariable model, revealed that only tenosynovitis was independently associated with HAQ-score (β=0.039, p&lt;0.001). Also when correcting for age, gender, joint counts, acute phase reactants and auto-antibodies this association remained (β=0.034, p&lt;0.001). MRI-detected inflammation at wrists or MCP-joints associated significantly with impairments in hand functioning (e.g. difficulties with opening milk cartons or jars). Exploring the relation between MRI-detected inflammation and HAQ-scores non-linear, suggested the presence of a ceiling effect, because after a certain inflammation-level, more inflammation was not associated with higher HAQ-scores. <h3>Conclusions</h3> MRI-detected inflammation, and tenosynovitis in particular, is associated with functional disability. This demonstrates the functional relevance of MRI-detected inflammation in early arthritis patients. <h3>References</h3> df <h3>Acknowledgement</h3> This work was supported by a Vidi-grant of the Netherlands Organisation for Scientific Research and the Dutch Arthritis Foundation <h3>Disclosure of Interest</h3> None declared
Hepatitis C Viral Infection Is Not Associated with Waldenstrom’s Macroglobulinemia.
Authors: Xavier Leleu, Kelly O’Connor, Allen Ho, Daniel D. Santos, Robert Manning, Lian Xu, Evdoxia Hatjiharissi, Olivier Tournilhac, Mariana Chemaly, Andrew R. Branagan, Zachary R. Hunter, Christopher J. Patterson, Kenneth C. Anderson, Steven Treon
Journal: Blood (2005)